Patorno et al. conducted a cohort study using a US commercial health plan database performed comparative analysis of propensity-score-matched incident new users of GLP-1ra versus DPP-4i, SU, and insulin, and reported non-significant differences in the composite CVD events (including acute myocardial infarction, unstable angina, ischemic or hemorrhagic stroke, or coronary revascularization, but not cardiovascular death) between study groups; the HRs (95% CI) were 1.20 (0.76–1.89), 1.05 (0.63–1.74), and 1.01 (0.73–1.41) for GLP-1ra versus DPP-4i, SU, and insulin, respectively [28]. The gene discussed is INS; the disease is acute myocardial infarction.